• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Roivant Sciences Receiving Interest in Bowel Disease Treatment, Bloomberg Says


Medication reportedly worth more than $7 billion.

Illustration of large intestine is on the woman's body. Business Woman touching belly painful suffering from enteritis. internal organs of the human body. inflammatory bowel disease. Image Credit: Adobe Stock Images/eddows

Image Credit: Adobe Stock Images/eddows

Roivant Sciences, a biotechnology company, is reportedly garnering interest in its inflammatory bowel disease treatment from major pharmaceutical companies. Expected to be worth over $7 billion, the drug is also being tested for the treatment of ulcerative colitis and Crohn’s disease. While deliberations have focused mainly on the treatment, it’s possible the entire company could be sold as well, according to insiders, requesting not to be identified due to the matter not being public.

Presently, there is no deal in place as Roviant could elect to keep the treatment, the insiders stated.

Reference: Roivant Attracts Interest for $7 Billion-Plus Bowel Drug. Bloomberg. July 6, 2023. Accessed July 10, 2023. https://www.bloomberg.com/news/articles/2023-07-06/roivant-said-to-attract-interest-for-7-billion-plus-bowel-drug#xj4y7vzkg

Related Videos
Related Content